Abstract: A cosmetic composition is provided which is a vanishing cream structured with 5 to 50% by weight of C12-C20 fatty acid, 0.1 to 20% by weight of C12-C20 fatty acid salt and hydrophilic composite particles with organic sunscreen agent. The hydrophilic composite particles are formed as a composite of sunscreen agent and a binder in a relative weight ratio of 5:1 to 1:10. The composition exhibits relatively high SPF photoprotection while maintaining excellent skinfeel aesthetics
FORM - 2
THE PATENTS ACT, 1970
(39 of 1970)
&
The Patents Rules, 2003
COMPLETE SPECIFICATION
(See Section 10 and Rule 13)
SUNSCREEN FORMULA VANISHING CREAM
HINDUSTAN UNILEVER LIMITED, a company incorporated under
the Indian Companies Act, 1913 and having its registered office
at 165/166, Backbay Reclamation, Mumbai -400 020, Maharashtra, India
The following specification particularly describes the invention and the manner in which it is to be performed
SUNSCREEN FORMULA VANAISHING CREAM
Field of the Inveretion
The invention concerns a form of vanishing cream as a cosmetic composition delivering a 5 high level of photoprotectlon with good skin aesthetics.
The delated Art
Vanishing creams are quite popular around the world. They spread easily on the skin giving a thin, semi-matte film which seems to disappear or "vanish". They are also used 10 to counteract shine which may arise from overactive sebaceous glands. Moreover, these creams counteract skin dryness to alleviate flaking, cracking and roughness.
The creams are formulated with high levels of stearic add suspended in water by an emulsifying agent. Typically the emulsifying agent is a potassium or sodium soap formed 15 by in situ reaction of caustic potash or other alkali on a portion of the stearic acid.
Ultraviolet radiation can be damaging to skin. Immediate damage may be in the form of erythema. More long term is the concern of initiating cancerous growth. For these reasons, photoprotective agents known as sunscreens have been incorporated into 20 cosmetic products. When the cosmetic product is a vanishing cream, we have found it is much more difficult to incorporate any high level of photoprotectlon while still maintaining desirable skinfeel properties.
WO-A-99/639S5 (Unilever) discloses personal washing compositions containing a 25 surfactant, a polymeric deposition aid and an encapsulated sunscreen. Particularly noted is use of SunCaps® 664, available from SunSmart Inc., which is an encapsulate of the sunscreen octyl methoxycinnamate.
Accordingly, the present invention is focused upon cosmetic compositions, particularly 30 vanishing creams, exhibiting not only a high level of photoprotectlon but also good aesthetic properties.
Summary of the Inventon A cosmetic composition is provided which includes: (i) from 5 to 50% by weight of a C12-C20 fatty acid; (ii) from 0. T to 20% by weight of a C12-C20"fatty acid salt: and 5 (li'i) from 0.1 to 20% by weight of hydrophilic composite particles formed of an organic sunscreen agent and a binder in a relative weight ratio of 5:1 to1:10.
Detailed Description of the invention
Now it has been found that cosmetic vanisliing creams can be formulated to achieve a significant level of photoprotective performance without any loss of skinfeel aesthetics. Photo protection is accomplished through hydrophiiic composite particles formed of a 5 binder and an organic sunscreen agent.
Fatty Acid Structurant
A first structurant component of vanishing cream compositions of the present invention is one or more of a C12-C20 fatty acid. Stearic acid is particularly preferred. Amounts of 10 fatty acid will range from 5 to 50%, preferably from 7 to 40%, more preferably from 10 to 25%, optimally from 12 to 20% by weight of the composition.
Advantageously the stearic acid may be present as asymmetric solid particles. Asymmetric is understood to mean that at least two of three dimensions on a majority of 15 the particles are not size identical. These particles can be oval or plate-like. Average particle size along greatest length may range from 0.01 to 500 micron and preferably from 1 to 100 micron. The particles are employed in the composition to impart a cream¬like viscosity. By virtue of being asymmetric, the particles deliver high skin friction.
20 A second component of the fatty acid structurant will be a salt of a C12-C20 fatty acid in amounts ranging from 0.1 to 20%, preferably from 0,5 to 10%, optimally from 1 to 4% by weight of the composition. Typically the salt forming cation may be selected from sodium, potassium, ammonium and triethanolammonium cations. Most preferred are potassium salts, particularly potassium stearate.
25
Hydrophiiic Composite Particles of Sunscreen Agent
Composite particles of the present invention will have a hydrophiiic outer surface. Hydrophilicity may be achieved through use of a hydrophiiic binder or via a hydrophiiic coating such as a silica or alumina coating. The binder may be hydrophiiic or
30 hydrophobic. Suitable categories of binder are polymers such as polyacrylates, polyvinylpyrrolidones, polyesters, polyamides, polyethers, polyolefins, polysaccharides including cellulose derivatives, starches, clays, hydrocarbons and combinations thereof.
Sunscreen agents can either be dispersed throughout the binder or can be formed as a core surrounded by binder.
Relative weight ratio of organic sunscreen agent to binder may range from 5:1 to 1:10, 5 preferably from 3:1 to 1:8, more preferably from 2:1 to 1:7, optimally from 1:1 to 1:3. Amounts of the binder may range from 10% to 99.5% by weight of the hydrophilic composite particles. More preferably weight of the binder may range from 30% to 98%, optimally from 50 to 85% by weight of the hydrophilic composite particles. Amounts of the sunscreen agent may range from 0,5 to 90%, preferably from 2 to 70%, optimally 10 from 30 to 50% by weight of the hydrophilic composite particles.
Amounts of the hydrophilic composite particles within the cosmetic composition may range from 0.1 to 30%, preferably from 2 to 15%, optimally from 4 to 10% by weight of the cosmetic composition. 15
Average particle size of the hydrophilic particles may range from 10 to 2,000 nm, preferably from 100 to 1,500 nm, and optimally from 200 to 1000 nm.
Sunscreen agents according to this invention will have at least one chromophoric group
20 absorbing within the ultraviolet ranging from 290 to 400 nm. Chromophoric organic
sunscreen agents may be divided into the following categories (with specific examples)
including: p-aminobenzoic acid, its salts and its derivatives (ethyl, isobutyl, glyceryl esters;
p-dimethylaminobenzoic acid); anthranilates (o-aminobenzoates; methyl, menthyl, phenyl,
benzyl, phenylethyl, linalyl, terpinyi and cyclohexenyl esters); salicylates (octyl, amyi,
25 phenyl, benzyl, menthyl, glyceryl and dipropyleneglycol esters); cinnamic acid derivatives
(menthyl and benzyl esters, alpha-phenyl cinnamonitrile; butyl cinnamoyl pyruvate);
dihydroxycinnamic acid derivatives (umbelliferone, methylumbelliferoneand methylaceto-
umbelliferone); trihydroxycinnamic acid derivatives (esculetin, methylesculetin, daphnetin,
and the glucosides, escuiin and daphnin); hydrocarbons (diphenylbutadiene and stiibene);
30 dibenzalacetone and benzalacetophenone; naphtholsulfonates (sodium salts of 2-
naphthol-3,6-disulfonic and of 2-naphthol-6,8-disulfonic acids); dihydroxy-naphthoic acid
and its salts; o- and p-hydroxybiphenyldisulfonates; coumarin derivatives (7-hydroxy, 7-
methyl and 3-phenyl); diazoles (2-acetyl-3-bromoindazole, phenyl benzoxazole, methyl
naphthoxazole and various aryl benzothiazoles); quinine salts (bisulfate, sulfate, chloride,
oleate and tannate); quinoline derivatives (8-hydroxyquinoline salts and 2-
phenylquinoline); hydroxy- or methoxy-substituted benzophenones; uric and vilouric acids;
tannic acid and its derivatives (e.g. hexaethyl ether); (butyl carbityi) (6-propyl piperonyl)
5 ether; hydroquinone; benzophenones (oxybenzone, sulisobenzone, dioxybenzone,
benzoresorcinol, 2,2',4,4'-tetrahydroxybenzophenone, 2,2'-dihydroxy-4,4'-
dimethoxybenzophenone, octabenzone); 4-isopropyldibenzoylnnethane;
butylmethoxydibenzoytmethane; etocryfene; and 4-isopropy[-dibenzoylnnethane.
10 Particularly useful sunscreen agents are: 2-ethylhexyl p-nnethoxycinnamate, 4,4'-t-butyl methoxydibenzoylmethane, 2-hydroxy-4-methoxybenzophenone, octyldimethyl p-aminobenzoic acid, digalloyltrioieate, 2,2-dihydroxy-4-methoxybenzophenone, ethyl 4-[bis(hydroxypropyl)]aminobenzoate, 2-ethylhexyl-2-cyano-3,3-d(phenylacrylate, 2-ethylhexylsalicylate, glyceryl p-aminobenzoate, 3,3,5-trimethylcyclohexylsalicylate,
15 methylanthranilate, p-dimethylaminobenzoic acid or aminobenzoate, 2-ethylhexyi p-
dimethylaminobenzoate, 2-phenylbenzimidazole-5-sulfonic acid, 2-(p-
dimethylanninophenyl)-5-sulfoniobenzoxazoicacid, 4-methylbenzylidene camphor, bis-ethylhexyloxyphenol methoxyphenol triazine, methylene bis-benzotriazolyl tetramethylbutyl phenol, dimethicodiethylbenzal malonate, isoamyl methoxycinnamate, 20 octyi triazone, terephthalidene dicamphor sulfonic acid and mixtures thereof.
Cosmetic compositions of this invention may not only have sunscreen agent held within but an amount of sunscreen agent may be formulated free of binder within the composition. When present outside the composite, the sunscreen agent may be available
25 in amounts from 0.1 to 25%, particularly from 2 to 15% by weight of the composition. Some preferred embodiments of this invention may be formulated without any sunscreen agent external to the composites or with only a relatively small amount external to the composite particles. For instance, the external sunscreen agent may range in amount from 0 to 5%, preferably from 0.01 to 2%, and possibly from 0.01 to 0.8% by weight of
30 the composition.
A number of hydrophilic composite particles with sunscreen agent are commercially available. A first commercial material is known as "Sun Caps" sold by Particle Sciences
Inc. of Bethlehem, Pennsylvania. Average particle size is reported to be approximately 250 nm. Sun Caps 664® is sold with a concentration of octylmethoxycinnamate (OMC) of 21.5% encapsulated in a binder that includes beeswax, carnauba wax, vinyl pyrrolidone/eicosene copolymer and emulsifiers (PEG-100 stearate, PEG-20, bis-PEG-12 5 dimethicone, sorbitar tristearate and Steareth-100). Sun Caps® are formed in a process revealed in US 5 733 531 herein incorporated by reference. The encapsulates are supplied as an aqueous dispersion containing up to 65% solids.
Another hydrophilic composite particulate commercially available is sold by Rona Division 10 of EMD Chemicals under the trademark Eusolex® UV-Pearls® OMC. UV Pearls® are prepared and described in US 7 264 795 herein incorporated by reference. Tliese composites are sold as particulates dispersed in an aqueous carrier. The particles are octylmethoxycinnamate coated with silica, polyvinylpyrrolidone and minor ingredients. These composites are sold as a dispersion in water. 15
Another useful hydrophilic composite particulate according to the present invention
utilizes a binder which is a condensation polymerized polyamide resin. A preferred
embodiment of this binder is a polyalkyleneoxypolyamide (referred to as an PAOPA resin)
and also an ester-terminated po(y(ester-amide) (referred to as an EPTEA resin). The
20 PAOPA resin can be prepared by reacting a monocarboxylic acid, a diamine compound,
and a dibasic acid. The EPTEA resin can be prepared by reacting a dibasic acid, a diamine,
a polyol and a mono alcohol. Preferably the EPTEA resin may be formed from reaction
of: (a) at least 50 equivalent percent of the dibasic acid comprising polymerized fatty
acid; (b) at least 50 equivalent percent of the diamine comprising ethylene diamine; (c)
25 10-60 equivalent percent of the total of the hydroxyl and amine equivalents provided by
diamine, polyol and monoalcohol are provided by monoalcohol; and (d) no more than 50
equivalent percent of the total of the hydroxyl and amine equivalents provided by
Chemical Company, Jacksonville, Florida. These resins are easily intimately mixed with
octylmethoxycinnamate (OMC) or other organic sunscreens to form a composite particulate with photo protective properties.
Hydrophiiic composite particulates which utilize as binder a condensation polymerized 5 polyamide resin can generally be prepared as follows. A vessel is charged with the resin and the organic sunscreen agent. These are heated up to 85-90°C and mixed until homogenous. The resultant homogeneous organic composition is then slowly poured with mixing into a second vessel containing heated water. Particles of the organic substance then congeal into particulates forming the composite resin/sunscreen. These 10 particulates can be easily separated as insoluble products from the water,
Optional Components
The composition of the present invention may contain a variety of other components to
enhance physical properties and performance.
15
Compositions of the present invention may include a cosmetically acceptable carrier. The carrier may be a liquid or solid material. Carriers may be present in amounts ranging from 5 to 98%, preferably from 20 to 95%, optimally from 40 to 80% by weight of the cosmetic compositions. Water is the most common carrier for this invention. Oily
20 carriers in the presence of water and an emulsifier will form emulsion systems as carriers. These systems may either be water-in-oil or oil-in-water emulsions. Besides water, suitable carrier classes include silicones, polyhydric alcohols, fatty alcohols, hydrocarbons, triglycerides and thickening powders.
25 Silicones when present may range from 5% to 60%, more preferably from 5% to 40%, by weight of the composition. These silicones may be organic, silicone-containing or fluorine-containing, volatile or non-volatile, polar or non-polar.
Particularly preferred volatile silicone oils are cyclic volatile silicones wherein the 30 repeating unit ranges from 3 to 5; and linear silicones wherein the repeating unit ranges from 1 to 7. Highly preferred examples of volatile silicone oils include cyclomethicones of varying viscosities, e.g., Dow Corning 200, Dow Corning 244, Dow Corning 245, Dow Corning 344 and Dow Corning 345 (commercially available from Dow Corning Corp.); SF-
1204 and SF-1202 Silicone Fluids, GE 7207 and 7158 (commercially available from G.E. Silicones) and SWS-03314 (commercially available from SWS Silicones Corp.
Hydrocarbons may be useful as cosmetically acceptable carriers for compositions of this 5 invention. They may include mineral oil, petrolatum and polyalpha-olefins. Examples of preferred volatile hydrocarbons include polydecanes such as isododecane and isodecane (e.g. PermethyI-99A which is available from Presperse Inc.) and the C7-C8 through C12-C15 isoparaffins (such as the Isopar Series available from Exxon Chemicals).
10 Polyhydric alcohols may serve as carriers. Illustrative of this group are propylyene glycol, dipropylene glycol, polypropylene glycol, polyethylene glycol, sorbitol, hydroxypropyl sorbitol, hexylene glycol, 1,3-butylene glycol, isoprene glycol, ethoxylated glycerol, propoxylated glycerol and mixtures thereof. Most preferred is glycerol known also as glycerin.
15
Fatty alcohols may also be useful carriers. The term "fatty" refers to carbon chain lengths ranging from 10 to 30 carbon atoms. Illustrative of this category are lauryl alcohol, cetyl alcohol, stearyl alcohol, isostearyl alcohol and combinations thereof.
20 Triglycerides are another group of materials useful as carriers. Illustrative but not limiting are sunflower seed oil, cotton oil, canola oil, soybean oil, castor oil, borage oil, olive oil, shea butter, jojoba oil and mixtures thereof. Mono- and di- glycerides may also be useful. Illustrative of these categories are glyceryl monostearate and glyceryl distearate.
25 The optional components, when incorporated into the composition, should be suitable for use in contact with human keratinous tissue without undue toxicity, incompatibility, instability, allergic response, and the like within the scope of sound judgment. The CTFA Cosmetic Ingredient Handbook, Second Edition (1992) describes a wide variety of non-limiting cosmetic and pharmaceutical ingredients commonly used in the skin care
30 industry, which are suitable for use in the compositions of the present invention. Examples of these classes include: abrasives, absorbents, aesthetic components such as fragrances, pigments, essential oils, skin sensates, astringents, etc. (e.g. clove oil, menthol, camphor, eucalyptus oil, eugenol, menthy! lactate and witch hazel distillate),
anti-acne agents, anti-caking agents, antifoaming agents, antimicrobial agents, antioxidants, biological additives, buffering agents, bulking agents, chelating agents, chemical additives, colorants, cosmetic astringents, cosmetic biocides, denaturants, drug astringents, external analgesics, film forming polymers, opacifying agents, pH adjusters, 5 propellants, reducing agents, sequestrants, skin bleaching and lightening agents, skin conditioning agents, skin soothing and/or healing agents and derivatives, skin treating agents, and vitamins and derivatives thereof.
In any embodiment of the present invention, however, the actives useful herein can be 10 categorized by the benefit they provide or by their postulated mode of action. However it is to be understood that the actives useful herein can in some instances provide more than one benefit or operate via more than one mode of action. Therefore, classifications herein are made for the sake of convenience and are not intended to limit the active to that particular application or applications listed. 15
The compositions may comprise a skin lightening agent. When used, the compositions preferably comprise from 0.1% to 10%, more preferably from 1% to 7%, and optimally from 3% to 5%, by weight of the composition, of a skin lightening agent. Suitable skin lightening agents include niacinamide, kojic acid, arbutin, tranexamic acid, placental 20 extract, ascorbic acid and derivatives thereof (e.g. magnesium ascorbyl phosphate, sodium ascorbyl phosphate, ascorbyl glucoside and ascorbyl tetraisopalmitates). Other skin lightening materials suitable for use herein include Actiwhite® (Cognis), Emblica® (Rona), Azeloglicina (Sinerga) and extracts (e.g. mulberry extract). Most preferred is niacinamide, also known as vitamin B3. 25
A safe and effective amount of an anti-oxidantradical scavenger may be added in amounts from 0.01% to 10%, more preferably from 0.1% to 5% by weight of the composition.
30 Anti-oxidants/radical scavengers may be employed such as ascorbic acid (vitamin C) and its salts, ascorbyl esters of fatty acids, ascorbic acid derivatives (e.g. magnesium ascorbyl phosphate), tocopherol (vitamin E), tocopherol sorbate, tocopherol acetate, other esters of tocopherol, butylated hydroxy benzoic acids and their salts, 6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxyIic acid (commercially available under the tradename Trolor®), amines (e.g. N,N-diethylhydroxylamine, amino-guanidine), nordihydroguaiaretic acid, bioflavonoids, amino acids, siiymarin, tea extracts and grape skin/seed extracts. Preferred anti-oxidants/radical scavengers are selected from esters of tocopherol, more 5 preferably tocopherol acetate.
The compositions of the present invention may optionally comprise a flavonoid compound. Flavonoids are disclosed in US 5 686 082 and US 5 686 367 herein incorporated by reference. Examples of flavonoids particularly suitable flavones, 10 isoflavones, coumanns, chromones, discoumarols, chromanones, chromanols, isomers (e.g. cis/trans isomers) thereof and mixtures thereof.
Preferred for use are flavones and isoflavones, in particular daidzein (7,4'-dihydroxy isoflavone), genistein (5,7,4'-trihydroxy isoflavone), equol (7,4'-dihydroxy isoflavan), 5,7-
15 dihydroxy-4'-methoxy isoflavone, soy isoflavones (a mixture extracted from soy) and mixtures thereof. Flavonoid compounds useful herein are commercially available from a number of sources, e.g. Indofine Chemical Company Inc., Stearloids Inc. and Aldrich Chemical Company Inc. The herein described flavonoid compounds are preferably present in from 0.01% to 20%, more preferably from 0.1% to 10%, and even more
20 preferably from 0.5% to 5% by weight.
Anti-inflammatory agents useful herein include ailantoin and compounds of the licorice (the plant genus/species Glycyrrhiza glabra) family, including glycyrrhetic acid, glycyrrhizic acid, and derivatives thereof (e.g. salts and esters). 25
The compositions may comprise a tanning active. When present, it is preferable that the compositions comprise from 0.1% to 20%, more preferably from 2% to 7% by weight of the composition. A preferred tanning active is dihydroxyacetone.
30 The compositions may comprise an antimicrobial or antifungal active. Such actives are capable of destroying microbes, preventing the development of microbes or preventing the pathogenic action of microbes. A safe and effective amount of an antimicrobial or antifungal active may be added to the present compositions, preferably, from 0.001% to
10%, more preferably from 0.01% to 5%, and even more preferably from 0.05% to 2% by weight of the composition.
Preferred examples of actives include those selected from the group consisting of salicylic 5 acid, benzoyl peroxide, 3-hydroxy benzoic acid, glycolic acid, lactic acid, 4-hydroxy benzoic acid, acetyl salicylic acid, 2-hydroxybutanoic acid, 2-hydroxypentanoic acid, 2-hydroxyhexanoic acid, cis-retinoic acid, trans-retinoic acid, retinol, phytic acid, N-acetyl-L-cystein, lipoic acid, azelaic acid, arachidonic acid, benzoyl peroxide, tetracycline, ibuprofen, naproxen, hydrocortisone, acetominophen, resorcinol, phenoxyethanol, 10 phenoxypropanol, phenoxyisopropanol, 2,4,4'-trichloro-2'-hydroxy diphenyl ether, 3,4,4'-trichlorocarbanilide, octopirox, ciclopirox, lidocaine hydrochloride, clotrimazole, climbazole, miconazole, ketoconazole, neocycin sulfate and mixtures thereof.
The compositions may comprise a conditioning agent selected from the group consisting
15 of humectants, moisturizers, or skin conditioners. A variety of these materials can be
employed and each can be present at a level of from 0.01% to 40%, more preferably
from 0.1% to 30%, and even more preferably from 0.5% to 15% by weight of the
composition. These materials include, but are not limited to, guanidine; urea; glycolic
acid and glycolate salts (e.g. ammonium and quaternary alkyl ammonium); lactic acid and
20 lactate salts (e.g. ammonium and quaternary alkyl ammonium); aloe vera in any of its
variety of forms (e.g., aloe vera gel); polyhydroxy compounds such as sorbitol, mannitol,
glycerol, hexanetriol, butanetrtol, propylene glycol, butylene glycol and hexylene glycol;
polyethylene glycols; sugars and starch derivatives (e.g. aikoxylated glucose, fructose,
sucrose, trehalose); hyaluronic acid; \actamide monoethanolamine; acetamide
25 monoethanolamine; sucrose polyester; petrolatum; and mixtures thereof.
The compositions can comprise one or more thickening agents, preferably from 0.05% to 10%, more preferably from 0.1% to 5%, and even more preferably from 0.25% to 4%, by weight for the composition. Non-limiting classes of thickening agents include those 30 selected from the group consisting of:
a. Carboxylic Acid Polymers
These polymers are crosslinked compounds containing one or more monomers
derived from acrylic acid, substituted acrylic acids, and salts and esters of these acrylic
acids and the substituted acrylic acids, wherein the crossiinking agent contains two or
5 more carbon-carbon double bonds and is derived from a polyhydric alcohol.
Examples of commercially available carboxylic acid polymers useful herein include the Carbomers, which are homopolymers of acrylic acid crosslinked with allyl ethers of sucrose or pentaerytritol. The Carbomers are available as the Carbopol® 900 series
10 from Noveon Corporation (e.g. Carbopol® 954). In addition, other suitable carboxylic
acid polymeric agents include copolymers of C10-30 alkyl acrylates with one or more monomers of acrylic acid, methacrylic acid, or one of their short chain (i.e. C1-4 alcohol) esters, wherein the crossiinking agent is an allyl ether of sucrose or pentae/ythritol. These copolymers are known as acrylates/C10-30 alkyl acrylate
15 crosspolymers and are commercially available as Carbopol® 1342, Carbopol® 1382,
Ultrez® 21, Pemulen® TR-1 and Pemulen® TR-2 from Noveon Corporation.
b. Taurate Polymers
The compositions of the present invention can optionally comprise crosslinked taurate
20 polymers useful as thickeners or gelling agents including anionic, cationic and
nonionic polymers. Examples include hydroxyethyl acrylate/sodium acryloyldimethyl taurate (e.g. Simulgel® NS and INS 100), acrylate/sodium acryloyldimethy! taurate (e.g. Simulgel® EG), sodium acryloyldimethyl taurate (e.g. Simulgel® 800) and ammonium acryloyldimethyl taurate/vinyl pyrrolidone (e.g. Aristoflex® AVC). 25
c. Polyacrylamide Polymers
The compositions of the present invention can optionally comprise vinyl polymerized
polyacrylamide polymers, especially nonionic polyacrylamide polymers including
substituted branched or unbranched polymers. Preferred among these
30 polyacrylamide polymers is the nonionic polymer given the CTFA designation
polyacrylamide and isoparaffin and laureth-7, available under the tradename Sepigel® 305 from Seppic Corporation.
other polyacrylamide polymers useful herein include multi-block copolymers of acrylamides and substituted acrylamides with acrylic adds and substituted acrylic acids. Commercially available examples of these multi-block copolymers include Hypan 5R150H, SS500V, SS500W and SS5A100H from Lipo Chemicals Inc. 5
d. Polysaccharides
A wide variety of polysaccharides are useful herein. "Polysaccharides" refer to gelling
agents that contain a backbone of repeating sugar (i.e. carbohydrate) units. Non-
limiting examples of polysaccharide gelling agents include those selected from the
10 group consisting of cellulose, carboxymethyl hydroxyethylcellulose,
hydroxyethylcellulose, hydroxyethyl ethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, methyl hydroxyethylcellulose, microcrystalline cellulose, sodium cellulose sulfate and mixtures thereof.
15 e. Gums and Clays
Other thickening and gelling agents useful herein include materials that are primarily derived from natural sources. Non-limiting examples include materials selected from the group consisting of acacia, agar, algin, alginic acid, ammonium alginate, amylopectin, calcium alginate, calcium carrageenan, carnitine, carrageenan, dextrin,
20 gelatin, gellan gum, guar gum, guar hydroxypropyltrtmonium chloride, hectorite,
laponite, bentonite, hyaluronic acid, hydrated silica, hydroxypropyl chitosan, hydroxypropyl guar, karaya gum, kelp, locust bean gum, natto gum, potassium carrageenan, propylene glycol alginate, sclerotium gum, sodium carboxymethyl dextran, sodium carrageenan, tragacanth gum, xanthan gum and mixtures thereof.
25
Particulate materials useful herein include but are not limited to bismuth oxychloride, sericite, mica, mica treated with barium sulfate or titanium dioxide, zeolite, kaolin, silica, boron nitride, lauroyl lysine, nylon, talc, styrene, polystyrene, ethylene/acrylic acid copolymer, aluminum oxide, silicone resin, barium sulfate, calcium carbonate,
30 cellulose acetate, PTFE, starch, modified starches, silk, glass and mixtures thereof.
Preferred organic powders/fillers include polymeric particles chosen from the methyisilsesquioxane resin microspheres such as those sold by Toshiba Silicone under the name Tospearl 145A; the spherical particles of crosslinked polydimethylsiloxanes,
especially such as those sold by Dow Corning Toray Silicone under the name Trefil E
506C or Trefil E 505C; spherical particles of polyamide and more specifically Nylon 12,
especially such as those sold by Atochem under the name Orgasol 2002N Nat COS;
polystyrene microspheres such as those sold by Dyno Particles under the name
5 Dynospheres; ethylene acrylate copolymer sold by Kobo under the name FloBead
EA209; PTFE; polypropylene; aluminum starch octenylsuccinate such as sold by
National Starch under the name Dry Flo; microspheres of polyethylene such as those
sold by Equistar under the name of Microthene FN510-00; silicone resin; platelet
shaped powder made from L-fauroy[ lysine and mixtures thereof. Especially preferred
10 are spherical powders with an average primary particle size from 0.1 to 75 microns,
preferably from 0.2 to 30 microns.
Except in the operating and comparative examples, or where otherwise explicitly indicated, all numbers in this description indicating amounts of material ought to be 15 understood as modified by the word "about".
The term "comprising" is meant not to be limiting to any subsequently stated elements but rather to encompass non-specified elements of major or minor functional importance. In other words the listed steps, dements or options need not be exhaustive. 20 Whenever the words "including" or "having" are used, these terms are meant to be equivalent to "comprising" as defined above.
All documents referred to herein, including all patents, patent applications, and printed publications, are hereby incorporated by reference in their entirety in this disclosure. 25
The following examples will more fully Illustrate the embodiments of this invention. All parts, percentages and proportions referred to herein and in the appended claims are by weight unless otherwise illustrated.
30 Examples 1-12
A series of comparison experiments were conducted to evaluate sunscreen efficacy and skinfeel properties in a number of vanishing cream compositions. Table I outlines formulas for these compositions,
INGREOIENr EXAMPLE (weight %)
1* 2* 3* 4* 5* 6* 7* 8 9 10 11 12
Glycerin 1.00 1.00 1.00 1.00 1.00 1,00 1.00 1.00 1.00 1.00 1.00 1.00
Potassum hydroxide (85% Assay) 0.57 0.57 0.57 0.S7 0.57 0,57 0.57 0.57 0.57 0.57 0.57 0.57
Disodium EDTA 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0,04 0.04 0.04 0.04 0,04
Methyl paraben 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20
Stearic add 17,90 17.90 17.90 17.90 17,90 17.90 17.90 17.90 17.90 17.90 17.90 17.90
Cetyf alcohol 0.53 0.53 0,53 0.53 0,53 053 0.53 0.53 0.53 0.53 0.53 0.53
Propyl paraben 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0,10 0.10
tsoprapyl mariistate 0.75 - 0.7S 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75
Octytmethoxydnnamate 1.20 4.00 1.20 1.20 _ - - - - - - -
Dimethicone 0.50 - 0.50 0.50 0.50 050 050 0.50 0.50 0.50 0.50 0.50
Micronized titanium dtoxitde 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20
Niacinamide 1.2S 1.25 3.00 5.00 1.25 3.00 5.00 1.25 1.25 1.25 3.00 5.00
Ailantoin 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20
Phenoxyethanol 0.20 0.20 0.20 0.20 0.20 0.20 0.20 020 0.20 0.20 0.20 0.20
Sodium ascorbyl phosphate 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20
SunCaps G&4(& - - - - - ~ ~ 5,00 - - - -
UVPea/b® 1 - - - - - "" - - 3.30 - - -
Sytvadear PA 1200V™ (1:1 with OMC — — — ~ _ — — — 2.4 2.4 2.4
Water Bal Bal Bal Bal Ba) Bal Bai Bat Bal Bal Bal Bal
SPF Value 3 7 3 3 1 1 1 IS 13 IS 15 15
GAP Valus at 103 seconds (mmtr10 301 " 767 698 253
■ 362 506 922 459 295 214 208
^Comparative examples
Test For Skinfel Properties
A "squeeze flow under constant force" procedure is used herein to study how easily a 5 lotion/cream is squeezed during application onto the skin. The larger the Gap Value (sample thickness), the more difficult it is to squeeze the sample. The Gap Value correlates with skinfeel properties as experienced by a consumer rn applying the (otion/cream sample to skin. Gap Values must lie between tolerance limits of 175 to 350. Within the tolerance range, the lower the gap value the better the skinfeel. 10
TJie procedure is conducted utilizing a Paar Physoca MCR 300 rheometer. Samples are compressed between concentric parallel plates (diameter of 25 mm for upper plate) and initial gap (vertical distance between the two plates) of 1 mm. The measurements are performed by squeezing the samples with a constant force of 12 Newton at ambient 15 condition (23-24°C- The time-dependence of sample thickness (gap) is measured over time and, in particular, the Gap Value recorded at 103 seconds (mmx 104).
Results
Composite particles represented by SunCaps 664®, UV-Pearls® and Sylvaclear 1200VTM (1:1 with OMC) were formulated into the respective examples 8-12 to have a total OMC sunscreen level of 1.2% by weight of the composition. 5
Example 1 exhibits a sun protective factor (SPF) of 3. In this composition, the sunscreen agent (OMC) is non-encapsulated. Examples 8-12 formulated with an equivalent 1.2% by weight of OMC but in encapsulated/composite format all exhibit SPF values of at least 13. Accordingly, in a stearic acid/stearate salt structuring system (i.e. a vanishing cream), 10 there is a significant boost in photo protection utilizing an encapsulate/composite form of sunscreen.
Examples 10-12 formulated with the Sylvaclear™ composite particles exhibited especially good performance. All of the Gap Values were less than 300. Accordingly, it is seen that
15 examples 10-12 not only exhibited a five-fold higher SPF value but also had better aesthetics (skinfeel) than those with non-composite free sunscreen agent of the example 1-4 formulas. Further, it is noted that increasing amounts of niacinamide improved (lowered) the Gap Value without any negative effects on SPF. These effects are seen in examples 10-12. A comparison with examples 5-7 reveals an opposite trend wherein Gap
20 Values increased rather than decreased as niacinamide concentration rose from 1.25% to 5%. Evidently there is a positive interaction between the Sylvaclear™ composite and that of niacinamide.
CLAIMS:
1. A cosmetic composition Comprising
(i) from 5 to 50% by weight of a C12-C20 fatly add;
5 (ii) from 0.1 to 20% by weight of a C12-C20 fatty aad salt;
{iii) from 0.1 to 20% by weight of hydrophlic composite particles formed of an organic
sunscreen agent and a binder in a relative weight ratio of 5:1 to 1:10,
wherein the cosmetic composition is a vanishing cream,
wherein the binder is a condensation polymerized poiyamide resin,
10 wherein the condaisation polymerized poiyamide resin is a polyakylenoxypotyamide or
an ester-terminated pol^ffiter-amide),
2. A composition according to daim 1 wherein the surscreen agerrt and binder are
intimately mixed together to fonm the composite particles.
15
3. A composition acGordtng to claim 1 or dalm 2 wherein the hydrophilic composite
particles have an average partide size ranging froml 10 to 2,000 nm.
4. A composition according to daim 3 wherein tiie hydrophilic composite partrdes have
20 an average partide size ranging from 100 to 1,500 nm.
5. A composition according to any one of the preceding daims further comprising from T
to 7% by weight of niadnamide.
| # | Name | Date |
|---|---|---|
| 1 | 2697-MUMNP-2010-FORM 3(10-12-2013).pdf | 2013-12-10 |
| 1 | 2697-MUMNP-2010-FORM-27 [28-08-2024(online)].pdf | 2024-08-28 |
| 2 | 2697-MUMNP-2010-FORM 3(10-11-2014).pdf | 2014-11-10 |
| 2 | 2697-MUMNP-2010-RELEVANT DOCUMENTS [29-09-2023(online)].pdf | 2023-09-29 |
| 3 | 2697-MUMNP-2010-RELEVANT DOCUMENTS [14-09-2022(online)].pdf | 2022-09-14 |
| 3 | 2697-MUMNP-2010-FORM-3-(25-04-2015).pdf | 2015-04-25 |
| 4 | Petition Under Rule 137 [18-11-2015(online)].pdf | 2015-11-18 |
| 4 | 2697-MUMNP-2010-RELEVANT DOCUMENTS [09-09-2021(online)].pdf | 2021-09-09 |
| 5 | 2697-MUMNP-2010-REPLY TO EXAMINATION REPORT(23-11-2015).pdf | 2015-11-23 |
| 5 | 2697-mumnp-2010-assignment.pdf | 2018-08-10 |
| 6 | 2697-MUMNP-2010-OTHER DOCUMENT(23-11-2015).pdf | 2015-11-23 |
| 6 | 2697-MUMNP-2010-Claims(AMENDED)-010216.pdf | 2018-08-10 |
| 7 | Other Document [02-06-2017(online)].pdf | 2017-06-02 |
| 8 | Form 26 [02-06-2017(online)].pdf | 2017-06-02 |
| 8 | 2697-mumnp-2010-claims.pdf | 2018-08-10 |
| 9 | 2697-MUMNP-2010-CORRESPONDENCE(2-3-2012).pdf | 2018-08-10 |
| 9 | Form 13 [02-06-2017(online)].pdf | 2017-06-02 |
| 10 | 2697-MUMNP-2010-CORRESPONDENCE(IPO)-(FER)-(18-3-2015).pdf | 2018-08-10 |
| 10 | 2697-MUMNP-2010-ORIGINAL UNDER RULE 6 (1A)-09-06-2017.pdf | 2017-06-09 |
| 11 | 2497-MUM-2010-ORIGINAL UNDER RULE 6 (1A)-09-06-2017.pdf | 2017-06-09 |
| 11 | 2697-mumnp-2010-correspondence.pdf | 2018-08-10 |
| 12 | 2697-mumnp-2010-description(complete).pdf | 2018-08-10 |
| 12 | 2697-MUMNP-2010-FORM 3-18-07-2017.pdf | 2017-07-18 |
| 13 | 2697-MUMNP-2010-Examination Report Reply Recieved-010216.pdf | 2018-08-10 |
| 13 | 2697-MUMNP-2010-PatentCertificate24-07-2017.pdf | 2017-07-24 |
| 14 | 2697-mumnp-2010-form 1.pdf | 2018-08-10 |
| 14 | 2697-MUMNP-2010_EXAMREPORT.pdf | 2018-08-10 |
| 15 | 2697-MUMNP-2010-FORM 13(13-2-2012).pdf | 2018-08-10 |
| 15 | 2697-mumnp-2010-wo international publication report a3.pdf | 2018-08-10 |
| 16 | 2697-mumnp-2010-wo international publication report a2.pdf | 2018-08-10 |
| 16 | 2697-MUMNP-2010-FORM 18(2-3-2012).pdf | 2018-08-10 |
| 17 | 2697-MUMNP-2010-PatentCertificateCoverLetter.pdf | 2018-08-10 |
| 17 | 2697-mumnp-2010-form 2(title page).pdf | 2018-08-10 |
| 18 | 2697-MUMNP-2010-OTHERS-010216.pdf | 2018-08-10 |
| 19 | 2697-mumnp-2010-form 2.pdf | 2018-08-10 |
| 19 | 2697-mumnp-2010-other document.pdf | 2018-08-10 |
| 20 | 2697-MUMNP-2010-FORM 3(12-8-2011).pdf | 2018-08-10 |
| 20 | 2697-MUMNP-2010-Original Under Rule 6(1 A)Form 3-270117.pdf | 2018-08-10 |
| 21 | 2697-MUMNP-2010-FORM 3(15-2-2011).pdf | 2018-08-10 |
| 21 | 2697-MUMNP-2010-MARKED COPY(CLAIMS)-010216.pdf | 2018-08-10 |
| 22 | 2697-MUMNP-2010-FORM 3(15-2-2012).pdf | 2018-08-10 |
| 22 | 2697-mumnp-2010-general power of attorney.pdf | 2018-08-10 |
| 23 | 2697-mumnp-2010-form pct-isa-210.pdf | 2018-08-10 |
| 23 | 2697-MUMNP-2010-FORM 3(22-6-2013).pdf | 2018-08-10 |
| 24 | 2697-MUMNP-2010-FORM 3(23-1-2013).pdf | 2018-08-10 |
| 24 | 2697-mumnp-2010-form pct-ipea-416.pdf | 2018-08-10 |
| 25 | 2697-MUMNP-2010-FORM 3(23-5-2014).pdf | 2018-08-10 |
| 25 | 2697-mumnp-2010-form pct-ipea-409.pdf | 2018-08-10 |
| 26 | 2697-MUMNP-2010-FORM 3(8-8-2012).pdf | 2018-08-10 |
| 26 | 2697-mumnp-2010-form 5.pdf | 2018-08-10 |
| 27 | 2697-MUMNP-2010-Form 3-091015.pdf | 2018-08-10 |
| 27 | 2697-MUMNP-2010-Form 5-010216.pdf | 2018-08-10 |
| 28 | 2697-MUMNP-2010-Form 3-160816.pdf | 2018-08-10 |
| 28 | 2697-mumnp-2010-form 3.pdf | 2018-08-10 |
| 29 | 2697-MUMNP-2010-Form 3-190316.pdf | 2018-08-10 |
| 30 | 2697-MUMNP-2010-Form 3-160816.pdf | 2018-08-10 |
| 30 | 2697-mumnp-2010-form 3.pdf | 2018-08-10 |
| 31 | 2697-MUMNP-2010-Form 3-091015.pdf | 2018-08-10 |
| 31 | 2697-MUMNP-2010-Form 5-010216.pdf | 2018-08-10 |
| 32 | 2697-MUMNP-2010-FORM 3(8-8-2012).pdf | 2018-08-10 |
| 32 | 2697-mumnp-2010-form 5.pdf | 2018-08-10 |
| 33 | 2697-MUMNP-2010-FORM 3(23-5-2014).pdf | 2018-08-10 |
| 33 | 2697-mumnp-2010-form pct-ipea-409.pdf | 2018-08-10 |
| 34 | 2697-MUMNP-2010-FORM 3(23-1-2013).pdf | 2018-08-10 |
| 34 | 2697-mumnp-2010-form pct-ipea-416.pdf | 2018-08-10 |
| 35 | 2697-mumnp-2010-form pct-isa-210.pdf | 2018-08-10 |
| 35 | 2697-MUMNP-2010-FORM 3(22-6-2013).pdf | 2018-08-10 |
| 36 | 2697-MUMNP-2010-FORM 3(15-2-2012).pdf | 2018-08-10 |
| 36 | 2697-mumnp-2010-general power of attorney.pdf | 2018-08-10 |
| 37 | 2697-MUMNP-2010-FORM 3(15-2-2011).pdf | 2018-08-10 |
| 37 | 2697-MUMNP-2010-MARKED COPY(CLAIMS)-010216.pdf | 2018-08-10 |
| 38 | 2697-MUMNP-2010-FORM 3(12-8-2011).pdf | 2018-08-10 |
| 38 | 2697-MUMNP-2010-Original Under Rule 6(1 A)Form 3-270117.pdf | 2018-08-10 |
| 39 | 2697-mumnp-2010-form 2.pdf | 2018-08-10 |
| 39 | 2697-mumnp-2010-other document.pdf | 2018-08-10 |
| 40 | 2697-MUMNP-2010-OTHERS-010216.pdf | 2018-08-10 |
| 41 | 2697-mumnp-2010-form 2(title page).pdf | 2018-08-10 |
| 41 | 2697-MUMNP-2010-PatentCertificateCoverLetter.pdf | 2018-08-10 |
| 42 | 2697-MUMNP-2010-FORM 18(2-3-2012).pdf | 2018-08-10 |
| 42 | 2697-mumnp-2010-wo international publication report a2.pdf | 2018-08-10 |
| 43 | 2697-MUMNP-2010-FORM 13(13-2-2012).pdf | 2018-08-10 |
| 43 | 2697-mumnp-2010-wo international publication report a3.pdf | 2018-08-10 |
| 44 | 2697-mumnp-2010-form 1.pdf | 2018-08-10 |
| 44 | 2697-MUMNP-2010_EXAMREPORT.pdf | 2018-08-10 |
| 45 | 2697-MUMNP-2010-Examination Report Reply Recieved-010216.pdf | 2018-08-10 |
| 45 | 2697-MUMNP-2010-PatentCertificate24-07-2017.pdf | 2017-07-24 |
| 46 | 2697-mumnp-2010-description(complete).pdf | 2018-08-10 |
| 46 | 2697-MUMNP-2010-FORM 3-18-07-2017.pdf | 2017-07-18 |
| 47 | 2497-MUM-2010-ORIGINAL UNDER RULE 6 (1A)-09-06-2017.pdf | 2017-06-09 |
| 47 | 2697-mumnp-2010-correspondence.pdf | 2018-08-10 |
| 48 | 2697-MUMNP-2010-ORIGINAL UNDER RULE 6 (1A)-09-06-2017.pdf | 2017-06-09 |
| 48 | 2697-MUMNP-2010-CORRESPONDENCE(IPO)-(FER)-(18-3-2015).pdf | 2018-08-10 |
| 49 | Form 13 [02-06-2017(online)].pdf | 2017-06-02 |
| 49 | 2697-MUMNP-2010-CORRESPONDENCE(2-3-2012).pdf | 2018-08-10 |
| 50 | 2697-mumnp-2010-claims.pdf | 2018-08-10 |
| 50 | Form 26 [02-06-2017(online)].pdf | 2017-06-02 |
| 51 | Other Document [02-06-2017(online)].pdf | 2017-06-02 |
| 52 | 2697-MUMNP-2010-Claims(AMENDED)-010216.pdf | 2018-08-10 |
| 52 | 2697-MUMNP-2010-OTHER DOCUMENT(23-11-2015).pdf | 2015-11-23 |
| 53 | 2697-MUMNP-2010-REPLY TO EXAMINATION REPORT(23-11-2015).pdf | 2015-11-23 |
| 53 | 2697-mumnp-2010-assignment.pdf | 2018-08-10 |
| 54 | Petition Under Rule 137 [18-11-2015(online)].pdf | 2015-11-18 |
| 54 | 2697-MUMNP-2010-RELEVANT DOCUMENTS [09-09-2021(online)].pdf | 2021-09-09 |
| 55 | 2697-MUMNP-2010-RELEVANT DOCUMENTS [14-09-2022(online)].pdf | 2022-09-14 |
| 55 | 2697-MUMNP-2010-FORM-3-(25-04-2015).pdf | 2015-04-25 |
| 56 | 2697-MUMNP-2010-RELEVANT DOCUMENTS [29-09-2023(online)].pdf | 2023-09-29 |
| 56 | 2697-MUMNP-2010-FORM 3(10-11-2014).pdf | 2014-11-10 |
| 57 | 2697-MUMNP-2010-FORM 3(10-12-2013).pdf | 2013-12-10 |
| 57 | 2697-MUMNP-2010-FORM-27 [28-08-2024(online)].pdf | 2024-08-28 |